Screening Compound Set for the Genesis screening library

NON-COMPETITIVE
COMBINED SYNOPSIS / SOLICITATION

Title: Acquisition of Screening Compound Set for the Genesis screening library

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued.

(ii) The solicitation number is 75N95019Q00194 and the solicitation is issued as a request for quotations.

This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures and FAR Part 12-Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold.

THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

The National Institute on Drug Abuse (NIDA), NIDA Office of Acquisitions - NCATS Section, on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Life Chemicals, inc., 26B Selden St., Woodbridge, CT 06525, for a library of 3,750 small molecules for the Genesis screening library.

(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2019-2 dated May 6, 2019.

(iv) The associated NAICS code is 325413 and the small business size standard is 1250 employees. No set-aside restriction is applicable.

(v) This acquisition consists of:

1. NCAT Screening Compound Set (scaffold-based, custom-selected screening compound library) consisting of 3750 compounds.

(vi) Requirements:

1. Contractor will provide small molecules that have been designed around analysis of available chemical and biological information, identification of key pathways modules/targets, computational and "wet biology" assessment of target druggability and potential binding domains.

2. Each compound shall be guaranteed to have a purity of >90% (accuracy +/-5%) confirmed by NMR and/or LCMS spectra. Contractor shall replace compounds that NCATS determines do not meet this standard.

3. Each compound shall be provided as follows: 8 uMol each, delivered in 800 uL of DMSO; matrix 2D barcoded tubes in racks to be proved by NCATS, 88 compounds per plate, column 1 empty; barcodes applied along the column 12 side of each rack.2.

4. Molecules shall be provided to NCATS in racks of barcoded Matrix 3711 racked tubes with column 1 removed. The tubes will be provided to the successful Contractor by NCATS after award. Contractor will apply barcodes, supply a platemap, and will apply Matrix 4430 capmats to seal the tubes after filling.

5. In addition to the molecules themselves, the Contractor shall provide the following electronic information for each required molecule: chemical structure or simplified molecular-input line-entry system (SMILES) or equivalent chemical structure information, supplier ID, plate ID, well location, tube ID, concentration in millimolar, and volume in microliters. This information shall be provided via email referencing individual compound vial barcodes.

6. The contractor shall ship the small molecules in the provided vials to NCATS.
(vii) Delivery shall be to:

The National Center for Advancing Translational Sciences (NCATS)
9800 Medical Center Drive
Rockville, MD 20850

Delivery shall be 4-8 weeks after receipt of order, offeror to specify FOB terms; however, offers must include shipping and handling costs, if any.

(viii) The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition.

(ix) Offers will be evaluated for technical criteria, price, and past performance, using a comparative evaluation. Technical criteria consist of matching the line items identified above. Technical and past performance, when combined, are significantly more important than price.

(x) Offerors are to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items, with offers.

(xi) The FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition.

The following FAR provisions or clauses are incorporated by reference:

52.204-7, System for Award Management (Oct 2018)
52.204-13, System for Award Management Maintenance (Oct 2018)
52.204-16, Commercial and Entity Code Reporting (Jul 2016)
52.204-18, Commercial and Entity Code Maintenance (Jul 2016)
HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015).

52.212-4(g), Invoice, is supplemented by the NIH Invoice and Payment Instructions (2/2014).

(xii) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition.

(xiii) This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. A determination by the Government whether to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered to determine whether to proceed on a non-competitive basis as indicated above, or to conduct a competitive procurement.

(xiv) In addition, the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

(xv) All responses must be received by 11:00 a.m. Eastern time on Tuesday, July 2, 2019, and reference solicitation 75N95019Q00194. Responses must be submitted by email to Stuart Kern, Contract Specialist, stuart.kern@nih.gov, 301-402-3334.

.